Red Light Holland Receives Official Psilocybin COA Through FDA-Compliant, DEA-Registered Partner, Irvine Labs, USA
Red Light Holland (OTCQB:TRUFF), a producer of functional mushrooms and psilocybin truffles, has achieved a significant milestone by receiving an official Certificate of Analysis (COA) through Irvine Labs, its FDA-compliant and DEA-registered partner in California.
The COA confirms psilocybin potency and process validation for potential medical grade manufacturing applications, following successful testing of naturally derived psilocybin truffles from the company's Netherlands facility. The partnership is advancing proprietary dehydration and packaging processes for extended shelf life while maintaining product integrity.
The company is preparing for a larger planned psilocybin export under Irvine Labs' 2025 DEA quota allocation, targeting emerging therapeutic markets, government-funded pilot programs, and clinical trials.
Red Light Holland (OTCQB:TRUFF), produttore di funghi funzionali e tartufi di psilocibina, ha raggiunto una tappa significativa ottenendo un certificato di analisi ufficiale (COA) tramite Irvine Labs, partner in California conforme alla FDA e registrato dalla DEA.
Il COA conferma la potenza della psilocibina e la validazione del processo per potenziali applicazioni di produzione medica, a seguito dei test riusciti sui tartufi di psilocibina derivati naturalmente dal facility nei Paesi Bassi. La partnership sta avanzando processi proprietari di disidratazione e confezionamento per una shelf-life estesa mantenendo l'integrità del prodotto.
L'azienda si sta preparando per una più ampia esportazione pianificata di psilocibina nell'ambito della quota 2025 di Irvine Labs per la DEA, con l'obiettivo di mercati terapeutici emergenti, programmi pilota finanziati dal governo e studi clinici.
Red Light Holland (OTCQB:TRUFF), productora de hongos funcionales y trufas de psilocibina, ha logrado una hito significativo al recibir un certificado de análisis oficial (COA) a través de Irvine Labs, su socio en California conforme a la FDA y registrado por la DEA.
El COA confirma la potencia de la psilocibina y la validación del proceso para posibles aplicaciones de fabricación de grado médico, tras las pruebas exitosas de trufas de psilocibina obtenidas de forma natural en la instalación de la empresa en los Países Bajos. La asociación está avanzando en procesos propietarios de deshidratación y envasado para una vida útil extendida sin comprometer la integridad del producto.
La empresa se prepara para una exportación de psilocibina planificada a mayor escala bajo la cuota DEA de 2025 de Irvine Labs, dirigidas a mercados terapéuticos emergentes, programas piloto financiados por el gobierno y ensayos clínicos.
Red Light Holland (OTCQB:TRUFF)는 기능성 버섯과 사이록시빈 트러플의 생산업체로, FDA 규정 준수 및 DEA 등록 파트너인 Irvine Labs를 통해 공식 분석 인증서(COA)를 수령하는 중요한 이정표를 달성했습니다.
COA는 네덜란드 시설에서 자연적으로 얻은 사이록시빈 트러플의 테스트를 마친 후 의료 등급 제조 적용 가능성을 위한 사이록시빈의 효능 및 공정 검증을 확인합니다. 파트너십은 제품 조성을 해치지 않으면서 향상된 보관 만료 기간을 위해 독자적인 탈수 및 포장 공정을 개발하고 있습니다.
회사는 Irvine Labs의 2025년 DEA 할당량에 따라 더 큰 규모의 사이록시빈 수출을 준비 중이며, 이는 신흥 치료 시장, 정부 주도 파일럿 프로그램 및 임상 시험을 목표로 합니다.
Red Light Holland (OTCQB:TRUFF), producteur de champignons fonctionnels et de truffes de psilocybine, a franchi une étape importante en recevant un Certificat d’Analyse officiel (COA) via Irvine Labs, partenaire en Californie conforme à la FDA et enregistré par la DEA.
Le COA confirme la puissance de la psilocybine et la validation du procédé pour des applications potentielles de fabrication médicale, à la suite des essais réussis des truffes de psilocybine dérivées naturellement de l’installation néerlandaise. Le partenariat fait progresser des procédés propriétaires de désydratation et d’emballage pour une durée de conservation prolongée tout en préservant l’intégrité du produit.
L’entreprise se prépare à une exportation de psilocybine à plus grande échelle sous la quota DEA 2025 d’Irvine Labs, ciblant des marchés thérapeutiques émergents, des programmes pilotes financés par le gouvernement et des essais cliniques.
Red Light Holland (OTCQB:TRUFF), Hersteller von funktionellen Pilzen und Psilocybin-Trüffeln, hat einen bedeutenden Meilenstein erreicht, indem sie offiziell ein Certificate of Analysis (COA) über Irvine Labs erhalten hat, dem FDA-konformen und DEA-registrierten Partner in Kalifornien.
Das COA bestätigt die Potenz von Psilocybin und Validierung des Prozesses für potenzielle medizinische Herstellungsanwendungen, nach erfolgreichen Tests an natürlich gewonnenen Psilocybin-Trüffeln aus dem niederländischen Werk. Die Partnerschaft arbeitet an proprietären Trocknungs- und Verpackungsprozessen für eine verlängerte Haltbarkeit, ohne die Produktintegrität zu beeinträchtigen.
Das Unternehmen bereitet sich auf eine größere geplante Psilocybin-Exporte im Rahmen des DEA-Kontingents 2025 von Irvine Labs vor und richtet sich an aufkommende therapeutische Märkte, staatlich geförderte Pilotprogramme und klinische Studien.
Red Light Holland (OTCQB:TRUFF)، منتجة للفطر الوظيفي وكراتPsilocybin، حققت إنجازاً هاماً بالحصول على شهادة تحليل رسمية (COA) من خلال Irvine Labs، الشريك في كاليفورنيا المتوافق مع FDA ومسجل لدى DEA.
تؤكد الشهادة فعالية السيليسباين والتحقق من العملية لتطبيقات التصنيع الطبي المحتملة، عقب اختبار ناجح لكرات Psilocybin المستخلصة طبيعياً من منشأة الشركة في هولندا. الشراكة تتقدم في تطوير عمليات التجفيف والتعبئة المميزة لمدة صلاحية أطول مع الحفاظ على تكامل المنتج.
تستعد الشركة لـ تصدير Psilocybin على نطاق أوسع بموجب حصة DEA لعام 2025 من Irvine Labs، مستهدفة أسواق علاجية ناشئة وبرامج تجريبية مدعومة من الحكومة وتجارب سريرية.
Red Light Holland (OTCQB:TRUFF)，功能性蘑菇与赛洛西宾松露的生产商，已通过其在加州的FDA 合规且经 DEA 注册的合作伙伴 Irvine Labs 获得正式的分析证书（COA），取得了重要里程碑。
COA 确认了 赛洛西宾效力与工艺验证，用于潜在的医疗级制造应用，基于公司荷兰设施自然提取的赛洛西宾松露经过成功测试。该合作关系正在推进专有的脱水和包装工艺，以延长货架期同时保持产品完整性。
公司正为在 Irvine Labs 2025 年 DEA 配额下的 更大规模的赛洛西宾出口做准备，目标是新兴治疗市场、政府资助的试点计划和临床试验。
- Successful validation of psilocybin potency through FDA-compliant and DEA-registered lab
- Confirmation of compatibility with medical grade manufacturing processes
- Development of proprietary dehydration and packaging processes for extended shelf life
- Planned expansion of psilocybin exports under DEA quota allocation
- None.
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms, mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws, announced today that it has received an official Certificate of Analysis (COA) through its research and development partner, Irvine Labs Inc., California, USA, confirming psilocybin potency and process validation for potential medical grade manufacturing applications.
The testing was conducted on Red Light Holland's naturally derived psilocybin truffles from its Netherlands facility, which were successfully shipped to the FDA-compliant and DEA-registered Irvine Labs facility in California, USA. Results confirm the materials are compatible with manufacturing processes being developed for potential medical grade applications.
Red Light Holland and Irvine Labs continue to advance proprietary dehydration and packaging processes designed to extend shelf life while maintaining product integrity.
Red Light Holland is also preparing for the next and larger planned psilocybin export under Irvine Labs existing 2025 DEA quota allocation.
This validation represents significant progress in the partnership between Red Light Holland and Irvine Labs as they work toward developing standardized psilocybin products aimed for emerging therapeutic markets, government-funded pilot programs, and clinical trials.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.
The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and Irvine lab's development of the Company's psilocybin; the Company and the Company's partners to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the expectations with respect to the Company's development work following the successful testing results of the psilocybin materials delivered to Irvine Labs; the Company's plans for continued development of dehydration and packaging processes by Irvine Labs; the Company's plans for future scheduled imports of psilocybin materials under Irvine Labs' existing 2025 DEA quota; the suitability of the Company's psilocybin materials for medical grade manufacturing applications; the Company's continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs Inc. and the research project to develop a process for the commercial manufacture of microdosing capsules derived from the Company's psilocybin truffles that could be used for medical grade applications; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving further important insights from naturally occurring psilocybin truffles; the Company's ability to extract and expand access to psilocybin products; the Company's ability to sell their product in future legal markets, as currently the company has no control on timing or policy change on future emerging markets, and the Company's ability to scalable production of high-quality, and approved microdosing capsules with extended shelf life via Irvine Labs ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the United States or around the world.
Forward-Looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' abilities, including Irvine Labs to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's ability to realize its plans for continued psilocybin development work following the successful testing results of the materials delivered to Irvine Labs; the Company's ability to successfully continue to export, development of dehydration and packaging processes through Irvine Labs; the Company's ability to execute future scheduled imports of psilocybin materials under Irvine Labs' existing 2025 DEA quota; the continued suitability of the Company's psilocybin materials for medical grade manufacturing applications; the Company's ability for its continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's ability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs and their research project to develop a process for the commercial manufacture of natural-source microdosing capsules derived from the Company's psilocybin truffles that could be used for medical grade applications; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the ability to extract and expand access to psilocybin products; and the Company's ability to have scalable production of high-quality, microdosing capsules with extended shelf life for Global Distribution and The Company's ability to continue shipping products to the United States and eventually the Company's ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the US or around the world.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' inabilities, including Irvine Labs, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's inability to realize upon its plans for continued psilocybin development despite the successful testing results; potential issues with ongoing development of dehydration and packaging processes; potential delays or complications with future scheduled imports under the existing DEA quota; changes in the suitability assessment of psilocybin materials for medical grade manufacturing applications; potential issues with future development work; the Company's inability to maintain its commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's inability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs; and The Company's ability to expand and extract access to psilocybin products.
The Company cannot make medical claims and is purely in a R&D phase with its partners Irvine Labs Inc.
Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268505
FAQ
What milestone did Red Light Holland (TRUFF) achieve with Irvine Labs in September 2025?
What is the significance of Red Light Holland's COA from Irvine Labs?
What are Red Light Holland's plans for psilocybin exports in 2025?
What processes are Red Light Holland and Irvine Labs developing for psilocybin products?
What markets is Red Light Holland targeting with its validated psilocybin products?
